Physician

Hwan G Jeong, M.D.

According to 2025 Medicare claims, Hwan Jeong, M.D. (NPI: 1366440604) practices hematology/oncology in the Bloomington, IL market, with the plurality of this provider's patient population coming from Mc Lean, IL. This provider's primary affiliated billing organization is MID-ILLINOIS HEMATOLOGY ONCOLOGY ASSOCIATES LTD (NPI: 1467467803; TIN: 371096341) and primary practice location at 61761-2192. Jeong is affiliated with the IRCCO (ACO ID: A2619), participating under the MSSP model.

Jeong's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 420 traditional Medicare patients, billed 218,298 HCPCS/CPT codes, and received $2,843,307 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,169 prescription claims across 182 beneficiaries totaling $2,454,714 in drug costs, led by Venclexta (Venetoclax). 2020 DME data shows 13 claims. Open Payments data shows 68 records totaling $2,152. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,519,042 and ending at $2,843,307. Concurrently, Part D prescription costs have risen steadily, from $893,498 to $2,454,714. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	430	118,171	$1,519,042
2016	499	125,821	$1,707,565
2017	519	195,869	$2,658,856
2018	571	178,031	$2,701,573
2019	547	234,317	$3,190,309
2020	495	207,078	$3,497,136
2021	465	213,108	$2,897,458
2022	434	198,709	$2,032,672
2023	472	251,937	$2,818,746
2024	420	218,298	$2,843,307

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	166	1,278	$893,498
2016	185	1,306	$1,143,632
2017	197	1,349	$1,405,260
2018	167	998	$1,250,670
2019	162	1,037	$1,504,209
2020	171	1,018	$1,396,838
2021	171	1,114	$1,627,738
2022	168	993	$1,707,869
2023	172	1,143	$1,925,184
2024	182	1,169	$2,454,714

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	48	$28,287
2016	N/R	51	$19,873
2017	N/R	42	$11,962
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	13	$1,522
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	391	1,360	$90
80053	Blood test, comprehensive group of blood chemicals	331	1,076	$10
36415	Insertion of needle into vein for collection of blood sample	340	1,538	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	343	1,643	$8
83615	Lactate dehydrogenase (enzyme) level	165	248	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Venclexta	Venetoclax	25	750	$327,984
Calquence	Acalabrutinib Maleate	15	450	$186,737
Eliquis	Apixaban	156	7,813	$150,112
Xarelto	Rivaroxaban	94	4,890	$85,864
Imatinib Mesylate	Imatinib Mesylate	13	630	$17,604

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	68	$2,152	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Hwan G. Jeong, M.D.?

Tedicare shows public-source Medicare data for Hwan G. Jeong, M.D. (NPI 1366440604), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Hwan G. Jeong, M.D. have ACO affiliation data?

Hwan G. Jeong, M.D. is shown with ACO affiliation data for IRCCO (MSSP, ACO ID A2619).

What billing organization is linked to Hwan G. Jeong, M.D.?

Hwan G. Jeong, M.D. is linked to MID-ILLINOIS HEMATOLOGY ONCOLOGY ASSOCIATES LTD (billing NPI 1467467803) in the available physician profile data.

Does Hwan G. Jeong, M.D. have Open Payments data?

Hwan G. Jeong, M.D. has 68 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.